Abbott to develop companion diagnostic test for investigational leukemia therapy
Under the agreement, Abbott will leverage its proprietary Vysis CLL fluorescence in situ hybridization (FISH) Probe kit to develop a test for identifying high-risk chronic lymphocytic leukemia (CLL)
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.